The company closed a Series A financing round in October 2014 with Barcelona-based VC firm “Inveready Technology Investment Group”. Inveready has over 70 M € under management through different funds, and has invested into Avizorex through its Life Sciences specialized fund “Inveready Innvierte Biotech II”.
EIT Health brings together leading healthcare companies across multiple industry sectors, public and private research centres, and top universities, to create a powerful network of partners with a clear mission: to accelerate entrepreneurship and innovation in healthy living and active ageing by providing Europe’s top talents with new opportunities and resources, for the benefit of all citizens.
In the national sphere, the CDTI has different instruments to fund R&D&i projects and to create and consolidate technology start-ups. Apart from the funding, the CDTI is entrusted with issuing the Reasoned Report to claim for a tax rebate on R&D&i activities.